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ABSTRACT
Basal cell carcinoma (BCC) is the most common skin cancer. It generally has an indolent course with low rates of 
metastasis and mortality. However, BCC is locally invasive and can cause significant morbidity due to destructive local 
spread. We report our experience with a patient who was referred to our skin cancer unit due to a previously neglected 
lesion on the parietal region of the scalp, which had developed for 7 years. The patient was prescribed vismodegib 
on the basis that surgery could cause excessive functional and aesthetic damage. The patient had an objective partial 
response after 20 months of treatment. He was then submitted to radical skin excision, leaving a large defect that was 
reconstructed using a free latissimus dorsi muscle flap. The patient recovered well, and at the 1-year follow-up there 
were no signs of local recurrence. Our case demonstrates the value of vismodegib treatment prior to surgery in a locally 
advanced, high-risk scalp BCC and highlights the importance of an individualized and specialized approach with these 
patients, within a multidisciplinary team. 
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INTRODUCTION
Basal cell carcinoma (BCC) is the most common 
cutaneous malignancy.1 It generally has an indolent 
course with low rates of metastasis and mortality. 
However, BCC is locally invasive and can cause significant 
morbidity due to destructive local spread. A broad 
range of therapeutic modalities is available for the 
treatment of BCC.2 The recent progress of more effective 
topical and non-surgical therapies has increased the 
treatment options for many lesions, although surgery and 
radiotherapy appear to be the most effective treatments, 
with surgery showing the lowest failure rates.3 For the 
majority of BCCs, simple excision is enough to achieve 
the cure. However, a small proportion of these tumors—
whether by anatomical location, size, and number of 
lesions or patient comorbidities—are not amenable to 
surgery. In recent years, inhibitors targeting the hedgehog 
(HH) pathway have shown great promise in this complex 
subset of patients.
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Mutations in HH pathway genes frequently occur 
primarily in BCC genes, encoding patched homolog 1 
(PTCH1), and smoothened homolog (SMO),4 and have 
been shown to play a role in the pathogenesis of 
sporadic BCC.5 PTCH mutations were found in 67% 
of the sporadic BCCs tumors.6 Due to the role of 
HH signaling in the pathogenesis of BCC, the HH 
signaling pathway has been the genetic basis for the 
development of BCC targeted therapies. The first 
HH-pathway inhibitor approved for patients with locally 
advanced, metastatic BCC, or who are not candidates 
for surgery or radiotherapy, was vismodegib.
Vismodegib is a small-molecule compound that 
selectively inhibits SMO. The initial phase 1 trial with 
vismodegib showed that from 33 patients with locally 
advanced or metastatic tumors, 18 had a response; in 
the remaining 15 patients, 11 had stable disease for 
up to 10.8 months and 4 had progressive disease.7 
The phase II trial ERIVANCE study8 confirmed the 
efficacy and safety of vismodegib in the management 
of advanced BCC and resulted in its approval in 2012. 
Its 12-month study update9 shows that the objective 
response rate increased from 30.3% to 33.3% in 
patients with metastatic disease, and from 42.9% 
to 47.6% in patients with the locally advanced form.
Vismodegib was also evaluated as a neoadjuvant 
followed by surgery for high-risk BCC. Overall, 
vismodegib reduced the surgical defect area by 27% 
from baseline and only one patient experienced 
recurrence.10 After a longer follow-up period of 
approximately 22 months, no further recurrences 
were seen.11 This strategy has been reported a few 
times in other studies.12-17 At this time, there are no 
randomized trial data to support the use of vismodegib 
as a neoadjuvant strategy, but data are increasing. 
Several clinical trials are ongoing to study the effect 
of vismodegib in this setting.18-21 Recently, the first 
results of a multicenter, non-comparative, open-label, 
phase 2 trial (VISMONEO study) evaluating the benefit 
of vismodegib as neoadjuvant treatment of BCC were 
released.22 This study includes patients with BCC of 
the face, inoperable or operable with functional or 
major aesthetic sequelae risk.23 Forty-four patients had 
a procedure after vismodegib treatment. Of these 44 
responders, 27 had a complete response proved by 
biopsy.23
Herein, we report the case of locally advanced 
BCC of the scalp and discuss the importance of 
multidisciplinary management, including neoadjuvant 
systemic treatment with vismodegib, surgery, and a 
reconstruction method.
CASE REPORT
A 61-year-old man with a medical history of type 2 
diabetes mellitus, ischemic heart disease, and smoking 
(30 pack-years), and no history of previous skin cancer, 
radiotherapy, or immunosuppressive treatment, was 
referred to our skin cancer unit due to a previously 
neglected lesion on the parietal region of the scalp, 
which had developed over the last 7 years. An incisional 
biopsy confirmed BCC. He presented good performance 
status (Eastern Cooperative Oncology Group [ECOG] 
score 0) and, on physical examination, the patient 
presented an extensive lesion, measuring 26 × 23cm, 
involving most of the left scalp and invading the left 
auditory canal. The lesion was ulcerated, exudative, 
and with spontaneous bleeding (Figure 1). No clinically 
detected regional lymph nodes and no bone affection 
was seen on computed tomography scan. After the 
initial evaluation, the tumor board decided that there 
was no indication for radiotherapy and that surgery 
could cause excessive functional and aesthetic damage, 
so systemic treatment was proposed.
Figure 1. The preoperative view of the giant (26 × 29 cm) 
basal cell carcinoma on the left side of the scalp.
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He was started on vismodegib 150 mg daily, 
2 months after the initial evaluation. During treatment, 
the patient experienced different adverse events, 
such as alopecia grade 2, dysgeusia grade 2, and 
muscular spasms grade 1. The patient had an objective 
partial response (35% reduction of tumor area) after 
20 months of treatment (Figures 2A and 2B).
Upon such a response, the tumor board once 
again discussed this patient’s case. The decision was 
made to propose surgery to him, given his overall 
good health state, his response to vismodegib, and 
his preference.
He underwent a radical skin excision in depth to 
the bony calvaria. The resection included the left auricle 
and left a large defect (20 × 20 cm) (Figures 3A and 3B). 
The reconstruction was performed using a free 
latissimus dorsi muscle flap with thoracodorsal 
vessels anastomosed to the left facial artery and vein 
(Figures 3C and 3D).
The patient recovered well, and 3 weeks later a 
second surgery was performed to cover the muscle 
with a split-thickness skin graft harvested from the 
posterior aspect of his right thigh. The patient was 
discharged after 10 days. At the 2-month follow-up, 
the patient revealed a completely healed free flap, and 
the residual scars of the recipient site were acceptable 
(Figure 4).
The histological evaluation report revealed a BCC 
with extensive areas of hyaline fibrosis (post-therapeutic) 
and foci of epidermoid differentiation. It invaded 
adipose tissue and auricular cartilage. Perineural 
invasion was observed, and the surgical margins were 
free. Three lymph nodes were identified, without 
metastases (Figure 5). Since then, the patient has had 
regular visits to our department with no relapse 1 year 
after surgery (Figures 6A and 6B).
DISCUSSION
This case illustrates some of the challenges 
in treating locally advanced BCC. Generally, the 
patient’s neglect is seen as the main reason for the 
extensive tumor growth, as was the case with this 
patient who had a disease duration of approximately 
7 years. The surgical resection of BCC is the treatment 
of choice, but limitations exist for these advanced 
tumors, mostly in locations that pose a challenge for 
the surgeon to completely remove the tumor and—
at the same time—preserve a satisfactory cosmetic 
appearance, with minimal impact on the patient’s 
Figure 2. A and B – The patient’s locally advanced scalp BCC regressed under treatment with neoadjuvant vismodegib 
but demonstrated multiples areas of drug resistance (after 20 months of treatment).
Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib
4-7 Autops Case Rep (São Paulo). 2019 Oct-Dec;9(4):e2019116
quality of life. In this case, vismodegib was used to 
control a very large lesion, and afterward, due to the 
good response, surgery was feasible. Vismodegib 
assumed a neoadjuvant role, potentially leading to a 
less morbid procedure.
The inconvenience associated with vismodegib 
treatment rel ies upon the side effects, which 
tend to incapacitate patients, leading to the high 
discontinuation rates. In the STEVIE trial, 36% of 
patients treated with vismodegib discontinued the 
treatment because of the adverse events, and 22% 
were recorded as having serious adverse events.24 
Our patient presented adverse events such as alopecia, 
dysgeusia, and muscular spasms, which occur when 
the patient has been taking the drug from 12 months 
or more, according to the known side effects of 
vismodegib therapy.24 However, none of adverse 
events was incapacitating and, except for alopecia, 
they all disappeared with treatment suspension.
Figure 3. A and B – Surgical defect (20 × 20 cm) after radical skin excision in depth to the bony calvaria and 
hemostasis. C – A free latissimus dorsi muscle flap was harvested and the thoracodorsal vessels (arrow) were 
anastomosed to the left facial artery and vein; the tunnel for the vascular pedicle had to be large enough to prevent 
any compression. D – Flap inset without tension. The edge of the scalp defect was elevated through the subgaleal 
plane and the muscle edge was sutured to the galea to improve the flap–scalp junction contour.
Figure 4. Surgical specimen with residual BCC and 
resistant areas. Almost all the specimen was occupied by a 
hemorrhagic neoplasm, partly flat and partly protruding, 
with 20 × 19.5 cm, which involved the auditory canal.
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Figure 5. A - Photomicrographs of the tumor showing the basal cell carcinoma (200X). B – Posttreatment squamous 
cell carcinoma differentiation, a common finding after treatment with vismodegib (200X). C – Sclerotic collagenous 
stroma (100X). D – Perineural invasion (100X).
Figure 6. Postoperative gross view (A and B). The patient received full-thickness skin grafts to cover the right scalp 
and the external auditory canal, shown here at 10 months (A and B) after surgery. Note the marked atrophy of the 
muscle, closely resembling the natural thickness of the native scalp.
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This patient has some negative factors predisposing 
him to tumor recurrence: (i) the length of time to 
diagnosis; (ii) the large size of the tumor; (iii) involvement 
of preauricular and postauricular sulci; (iv) an infiltrative 
growth pattern; (v) perineural involvement; and 
(vi) poorly defined borders after vismodegib treatment. 
However, we achieved tumor-free surgical margins, 
which are paramount for disease control, and still had 
an acceptable aesthetic outcome.
Another important issue in the treatment of locally 
advanced BCC tumors, is the choice of the appropriate 
method of reconstruction. Reconstructive options are 
determined by the extent of the defect, focusing the 
primary wound healing with aesthetic and functional 
outcomes. Microsurgical reconstruction offers the 
advantage of a single-stage closure of large defects 
with well-vascularized tissue, particularly in this case of 
scarred tissue. The latissimus dorsi muscle is one of the 
most used free flaps because of its safety and relative 
ease of acquisition. The large size of the latissimus 
dorsi muscle allows for a broad coverage providing 
proper contours on a large scalp defect and often 
leaving an acceptable cosmetic result.25-28 This patient 
had some risk factors for microsurgical reconstruction 
(type 2 diabetes mellitus, ischemic heart disease, 
and smoking), which were taken into consideration 
regarding the choice of the flap. The good caliber of 
the vascular pedicles, the excellent trophic quality, 
and the reliability of the flap were critical in the final 
decision. In this patient, it was not possible to perform 
an anastomosis with superficial temporal vessels due 
to tumor involvement, so anastomosis was made to 
the facial vessels.
This case has demonstrated the potential benefit 
of the utilization of vismodegib in combination with 
surgery to treat advanced BCC. Additionally, it is 
important to underscore that the management of 
these complex patients is challenging. It requires an 
individualized and highly specialized approach and 
demands close collaboration between the surgical and 
oncological team in order to determine appropriate 
treatment options.
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